Unknown

Dataset Information

0

Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators.


ABSTRACT: Pulmonary fibrosis (PF) can arise from unknown causes, as in idiopathic PF, or as a consequence of infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Current treatments for PF slow, but do not stop, disease progression. We report that treatment with a runt-related transcription factor 1 (RUNX1) inhibitor (Ro24-7429), previously found to be safe, although ineffective, as a Tat inhibitor in patients with HIV, robustly ameliorates lung fibrosis and inflammation in the bleomycin-induced PF mouse model. RUNX1 inhibition blunted fundamental mechanisms downstream pathologic mediators of fibrosis and inflammation, including transforming growth factor-β1 and tumor necrosis factor-α, in cultured lung epithelial cells, fibroblasts, and vascular endothelial cells, indicating pleiotropic effects. RUNX1 inhibition also reduced the expression of angiotensin-converting enzyme 2 and FES Upstream Region (FURIN), host proteins critical for SARS-CoV-2 infection, in mice and in vitro. A subset of human lungs with SARS-CoV-2 infection overexpress RUNX1. These data suggest that RUNX1 inhibition via repurposing of Ro24-7429 may be beneficial for PF and to battle SARS-CoV-2, by reducing expression of viral mediators and by preventing respiratory complications.

SUBMITTER: O'Hare M 

PROVIDER: S-EPMC8059259 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3308800 | biostudies-literature
| S-EPMC8938595 | biostudies-literature
| S-EPMC1568942 | biostudies-literature
| S-EPMC7928547 | biostudies-literature
| S-EPMC521800 | biostudies-literature
| S-EPMC7893688 | biostudies-literature
| S-EPMC548959 | biostudies-literature
| S-EPMC2258931 | biostudies-literature
2012-06-20 | E-GEOD-30589 | biostudies-arrayexpress
| S-EPMC544093 | biostudies-other